Response rate at 6 weeks after start of therapy (after 2 initial courses) [clinicaltrials_resource:4e772fdb8a882f21887ef997a4defd9c]
Response rate will be defined as the proportion of patients who achieved complete response or partial response (CR+PR) using the World Health Organization (WHO) criteria evaluated after two initial courses of temsirolimus, temozolomide and irinotecan in previously untreated patients with high risk ESFT. Participants who are treated in Group B with DSRCT or those who do not receive window therapy will not be included in this analysis.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Response rate at 6 weeks after start of therapy (after 2 initial courses) [clinicaltrials_resource:4e772fdb8a882f21887ef997a4defd9c]
Response rate will be defined as the proportion of patients who achieved complete response or partial response (CR+PR) using the World Health Organization (WHO) criteria evaluated after two initial courses of temsirolimus, temozolomide and irinotecan in previously untreated patients with high risk ESFT. Participants who are treated in Group B with DSRCT or those who do not receive window therapy will not be included in this analysis.
Bio2RDF identifier
4e772fdb8a882f21887ef997a4defd9c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4e772fdb8a882f21887ef997a4defd9c
measure [clinicaltrials_vocabulary:measure]
Response rate
time frame [clinicaltrials_vocabulary:time-frame]
at 6 weeks after start of therapy (after 2 initial courses)
description
Response rate will be defined ...... be included in this analysis.
identifier
clinicaltrials_resource:4e772fdb8a882f21887ef997a4defd9c
title
Response rate at 6 weeks after start of therapy (after 2 initial courses)
@en
type
label
Response rate at 6 weeks after ...... 72fdb8a882f21887ef997a4defd9c]
@en